Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

This study is looking at how certain genes affect how Egyptian patients with liver cancer (hepatocellular carcinoma, or HCC) respond to a drug called sorafenib, which is used to treat this type of cancer. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with hepatocellular carcinoma (HCC) - You have not yet been treated with a type of drug called a TKI (tyrosine kinase inhibitor) **You may NOT be eligible if...** - Your liver tumor is not HCC (e.g., it is a different type) - Your liver function is classified as Child-Pugh grade C (severely impaired) - You have another type of cancer - You have a chronic inflammatory condition - You have severe heart, lung, or kidney problems - You are allergic to or cannot tolerate sorafenib - You have severe uncorrectable blood clotting problems - You are under 18 years old Talk to your doctor to see if this trial is right for you.